NCT05014685

PPI-amoxicillin for H. Pylori Treatment

Proton Pump Inhibitor and Amoxicillin Combined Bismuth or Metronidazole for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 732 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled clinical trial will identify the additional benefit of bismuth or metronidazole in proton pump inhibitor-amoxicillin-containing therapy for Helicobacter pylori first-line treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Rabeprazole	20mg bid
DRUG	Bismuth potassium citrate	0.6g bid
DRUG	Metronidazole	0.4g tid
DRUG	Amoxicillin	1g tid

Timeline

• Start date: 2021-08-20
• Primary completion: 2022-12-30
• Completion: 2022-12-30
• First posted: 2021-08-20
• Last updated: 2021-08-23

Locations

1 site across 1 country: China